|
| Wednesday, 10 July 2019, 13:27 JST | |
| |  | |
Source: Eisai | |
|
|
|
|
A Focused Drug Discovery Approach That Integrates Human Genetics/ Data Science/ Precision Chemistry
|
TOKYO, July 10, 2019 - (JCN Newswire) - Eisai Co., Ltd. has announced that the Eisai Center for Genetics Guided Dementia Discovery (G2D2), a new exploratory research facility in Cambridge, Massachusetts, U.S., held its opening ceremony and has begun full-scale research activities.
 | | (Standing from left to right) Ryan Fattman, U.S. Senator for Massachusetts; Mike Belleville, patient living with dementia; Haruo
Naito, Eisai CEO; Yoshito Kishi, Morris Loeb Professor of Chemistry, Harvard University; Yasushi Nakamura, Acting Consul General
at Consulate General of Japan in Boston; Mark Fuller, Undersecretary for Business Growth, Executive Office of Economic
Development. |
G2D2 integrates Eisai's strengths cultivated from human genetics, data sciences and precision chemistry for the novel drug discovery approach, and this approach will focus on the immunodementia to expand Eisai's dementia pipeline beyond amyloid-beta (A beta) and tau. Specifically, G2D2 will leverage human genetics and human biology to attempt to discover potential innovative medicines for dementia, which target the brain?s immune system.
G2D2 is located in Cambridge, Massachusetts, one of the world?s leading biotechnology clusters where academic institutions and private research organizations are concentrated, and will collaborate with the world-class science. Taking advantage of the benefits of its location, The Eisai Incubator for
NeuroDiscovery (e-IND) will provide space to Cambridge-based start-up/spin-out companies conducting high-risk but potentially transformative research that can impact the discovery of breakthrough neuroscience therapeutics. G2D2 also plans to contribute to the development of next-generation scientific leaders in the Boston and Cambridge areas through internships, training programs and postdoctoral fellowships in genetics and drug discovery science.
With the full-scale operation of G2D2, Eisai is striving to discover innovative dementia treatments using a multi-dimensional, comprehensive approaches to fulfill unmet needs and increase the benefits for patients and their families.
Contact:
Media Inquiries
Public Relations Department
Eisai Co., Ltd.
+81-(0)3-3817-5120
Topic: Press release summary
Source: Eisai
Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
